Anti-tumoral capabilities of effector cells after IFN-α or CpG-motif treatment of cocultured dendritic cells

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 6, 2006, Pages 403-409

  Erhardt, Michael ^a,b   Schmidt Wolf, Ingo G H ^a   Sievers, Elisabeth ^a   Frank, Susanne ^a   Strehl, John ^a   Von Lilienfeld Toal, Marie ^a   Gorschlüter, Marcus ^a  

^a UNIVERSITY OF BONN   (Germany)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

CIK cells; CpG ODN; Dendritic cells; Interferon ; Interleukin 4; LAK cells

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; HLA ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; COCULTURE; CYTOTOXICITY; CYTOTOXICITY TEST; DENDRITIC CELL; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; NORMAL HUMAN; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL COMMUNICATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; CPG ISLANDS; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-4; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; NEOPLASMS; OLIGONUCLEOTIDES;

EID: 33845717693     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0048-5     Document Type: Article

References (27)

1. Dauer M., Pohl K., Obermaier B., Meskendahl T., Robe J., Schnurr M., Endres S. and Eigler A. (2003): Interferon-alpha disables dendritic cell precursors: dendritic cells derived from interferon-alpha-treated monocytes are defective in maturation and T-cell stimulation. Immunology, 110, 38-47.
2. Della Bella S., Nicola S., Riva A., Biasin M., Clerici M. and Villa M. L. (2004): Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J. Leukoc. Biol., 75, 106-116.
3. + dendritic cells. Eur. J. Immunol., 33, 358-367.
4. Erhardt M., Gorschlüter M., Sager J., Ziske C., Strehl J., von Lilienfeld-Toal M. and Schmidt-Wolf I. G. (2005): Transfection of human monocyte-derived dendritic cells with CpG oligonucleotides. Immunol. Cell Biol., 83, 278-285.
5. Gabriele L., Borghi P., Rozera C., Sestili P., Andreotti M., Guarini A., Montefusco E., Foa R. and Belardelli F. (2004): IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood, 103, 980-987.
6. Grimm E. A., Mazumder A., Zhang H. Z. and Rosenberg S. A. (1982): Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155, 1823-1841.
7. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S. and Hartmann G. (2002): Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol., 168, 4531-4537.
8. Itoh K., Shiiba K., Shimizu Y., Suzuki R. and Kumagai K. (1985): Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J. Immunol., 134, 3124-3129.
9. Krieg A. M. (2002): CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol., 20, 709-760.
10. Leemhuis T., Wells S., Horn P., Scheffold C., Edinger M. and Negrin R. S. (2000): Autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin's disease. Blood, 96, 3624 (abstract).
11. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol., 153, 1687-1696.
12. Marten A., Flieger D., Renoth S., Weineck S., Albers P., Compes M., Schottker B., Ziske C., Engelhart S., Hanfland P., Krizek L., Faber C., von Ruecker A., Muller S., Sauerbruch T. and Schmidt-Wolf I. G. (2002): Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial. Cancer Immunol. Immunother., 51, 637-644.
13. Marten A., Greten T., Ziske C., Renoth S., Schottker B., Buttgereit P., Schakowski F., von Rucker A., Sauerbruch T. and Schmidt-Wolf I. H. (2002): Generation of activated and antigen-specific T cells with cytotoxic activity after coculture with dendritic cells. Cancer Immunol. Immunother., 51, 25-32.
14. Marten A., Renoth S., von Lilienfeld-Toal M., Buttgereit P., Schakowski F., Glasmacher A., Sauerbruch T. and Schmidt-Wolf I. G. (2001): Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica, 86, 1029-1037.
15. Marten A., Ziske C., Schottker B., Renoth S., Weineck S., Buttgereit P., Schakowski F., von Rucker A., Sauerbruch T. and Schmidt-Wolf I. G. (2001): Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J. Immunother. 24, 502-510.
16. Paquette R. L., Hsu N. C., Kiertscher S. M., Park A. N., Tran L., Roth M. D. and Glaspy J. A. (1998): Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol., 64, 358-367.
17. Ridgway D. (2003): The first 1000 dendritic cell vaccinees. Cancer Invest., 21, 873-886.
18. Romani N., Gruner S., Brang D., Kampgen E., Lenz A., Trockenbacher B., Konwalinka G., Fritsch P. O., Steinman R. M. and Schuler G. (1994): Proliferating dendritic cell progenitors in human blood. J. Exp. Med., 180, 83-93.
19. Santini S. M., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T. and Belardelli F. (2000): Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med., 191, 1777-1788.
20. Schattenberg D., Schott M., Reindl G., Krueger T., Tschoepe D., Feldkamp J., Scherbaum W. A. and Seissler J. (2000): Response of human monocyte-derived dendritic cells to immunostimulatory DNA. Eur. J. Immunol., 30, 2824-2831.
21. Schmidt-Wolf I. G., Finke S., Trojaneck B., Denkena A., Lefterova P., Schwella N., Heuft H. G., Prange G., Korte M., Takeya M., Dorbic T., Neubauer A., Wittig B. and Huhn D. (1999): Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br. J. Cancer, 81, 1009-1016.
22. Schmidt Wolf I. G., Lefterova P., Johnston V., Huhn D., Blume K. G. and Negrin R. S. (1994): Propagation of large numbers of T cells with natural killer cell markers. Br. J. Haematol., 87, 453-458.
23. Schmidt Wolf I. G., Lefterova P., Mehta B. A., Fernandez L. P., Huhn D., Blume K. G., Weissman I. L. and Negrin R. S. (1993): Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol., 21, 1673-1679.
24. Schmidt Wolf I. G., Negrin R. S., Kiem H. P., Blume K. G. and Weissman I. L. (1991): Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J. Exp. Med., 174, 139-149.
25. Shi M., Zhang B., Tang Z. R., Lei Z. Y., Wang H. F., Feng Y. Y., Fan Z. P., Xu D. P. and Wang F. S. (2004): Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J. Gastroenterol., 10, 1146-1151.
26. Wang F. S., Liu M. X., Zhang B., Shi M., Lei Z. Y., Sun W. B., Du Q. Y. and Chen J. M. (2002): Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J. Gastroenterol., 8, 464-468.
27. Whiteside T. L. and Odoux C. (2004): Dendritic cell biology and cancer therapy. Cancer Immunol. Immunother., 53, 240-248.